With Claimed Perfecting Feature In Contents (e.g., Excipient, Lubricant, Etc.) Patents (Class 424/465)
-
Patent number: 9387191Abstract: Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).Type: GrantFiled: July 21, 2010Date of Patent: July 12, 2016Assignee: Keryx Biopharmaceuticals, Inc.Inventor: Henry Trong Le
-
Patent number: 9387252Abstract: Pharmaceutical compositions of a low-solubility drug and lower alkanoate-, phthalate- and trimellitate esters of hydroxypropyl methyl cellulose and lower alkanoate- and succinate esters of cellulose and methyl cellulose are disclosed that provide enhanced concentrations of the drug in a use environment.Type: GrantFiled: December 17, 2013Date of Patent: July 12, 2016Assignee: Bend Research, Inc.Inventors: Walter C. Babcock, Dwayne T. Friesen, Warren K. Miller, Daniel T. Smithey, David K. Lyon
-
Patent number: 9386783Abstract: Agglomerates comprising calcium-hydrocolloid-composite materials and at least one sugar alcohol, as well of methods for preparing the agglomerates and various applications thereof.Type: GrantFiled: July 31, 2007Date of Patent: July 12, 2016Assignees: SÜDZUCKER AKTIENGESELLSCHAFT MANNHEIM/OCHSENFURT, HENKEL AG & CO. KGAAInventors: Stephan Hausmanns, Tillmann Dörr, Jörg Kowalczyk, Rainer Kliss, Tilo Poth, Badr Nfissi, André Schirlitz
-
Patent number: 9358208Abstract: Disclosed is a bolus comprising: a bolus body comprising a matrix material and one or more biologically beneficial substances contained in and/or on the matrix; wherein the exterior surface of the bolus body is shaped so as to have a least one recessed portion; and at least part of the recessed portion of the bolus body is coated with a material which retards or inhibits release of the beneficial substance(s) from the matrix.Type: GrantFiled: June 10, 2013Date of Patent: June 7, 2016Assignee: Animax LtdInventor: William Leslie Porter
-
Patent number: 9345698Abstract: There is provided pharmaceutical compositions for the treatment of pain e.g. short-term pain, which compositions comprise a mixture comprising: (a) microparticles of alfentanil, or a pharmaceutically acceptable salt thereof, which microparticles are presented on the surfaces of larger carrier particles; (b) a water-soluble weak base; and (c) a compound which is a weak acid, which acid is presented in intimate mixture with the microparticles of alfentanil or salt thereof. The composition may further comprise a disintegrant. The acid is preferably citric acid.Type: GrantFiled: July 15, 2014Date of Patent: May 24, 2016Assignee: Orexo ABInventors: Anders Pettersson, Barbro Johansson, Emil Schwan
-
Patent number: 9339464Abstract: The present invention relates to a fast dissolving granulate formulation containing the veterinary drug azaperone and a method for preparing said granulate formulation.Type: GrantFiled: June 21, 2012Date of Patent: May 17, 2016Assignee: Elanco Animal Health Ireland LimitedInventors: Dieter Bert Leen Ameye, Lieven Van Vooren, Peter Meerts, Geert Louise F. Van Beeck, Raja Satyanarayana Yekkala
-
Patent number: 9320718Abstract: A pharmaceutical composition in multilayer-coated form including an omega-3 fatty acid or an alkyl ester thereof and a statin-based drug, and more particularly, a pharmaceutical composition for oral administration including: (a) a gelatin capsule core containing an omega-3 fatty acid or an alkyl ester thereof; (b) a first coating layer formed by coating, on the gelatin capsule core, hydroxypropyl methylcellulose and a copolymer of butyl methacrylate, (2-demethylaminoeethyl) methacrylate, and methyl methacrylate at a weight ratio of 1:2:1; and (c) a second coating layer formed by coating, on the first coating layer, a coating solution containing a statin-based drug.Type: GrantFiled: May 21, 2013Date of Patent: April 26, 2016Assignee: KUHNIL PHARM. CO., LTD.Inventors: Jae-Pyoung Cho, Pung-Sok Lee, Seul-A Lee, Min-Ho Jeong, Mase Lee
-
Patent number: 9308263Abstract: The invention features pharmaceutical compositions including (i) a drug, and (ii) a PEG fatty acid ester or PPG fatty acid ester in an amount sufficient to increase the oral bioavailability of the drug.Type: GrantFiled: October 19, 2012Date of Patent: April 12, 2016Assignee: Seachaid Pharmaceuticals, Inc.Inventors: Balasingam Radhakrishnan, Anuradha Vaidya, Navdeep Balkrishna Malkar, Karen Polowy, Kenneth Duke James, Jr.
-
Patent number: 9301948Abstract: An instantly wettable and rapidly disintegrating oral film dosage form without a surfactant and without a polyalcohol was achieved by combining at least one water soluble polymer that is not a copolymer of vinylpyrrolidone, at least one active agent, a copolymer of vinylpyrrolidone and titanium dioxide. In certain embodiments, the film comprises hydroxypropyl cellulose or a combination of hydroxypropyl cellulose and a polymer or copolymer of vinylpyrrolidone or a substituted vinylpyrrolidone as the water soluble polymer(s). A plasticizer, and optional additives selected from synthetic sweeteners, natural sweeteners, flavorants, antioxidants, colorants, and opacifiers, can be added to the disclosed film oral dosage forms.Type: GrantFiled: July 30, 2014Date of Patent: April 5, 2016Assignee: IntelGenx Corp.Inventors: Horst G. Zerbe, Angela Angusti, Nadine Paiement
-
Patent number: 9283227Abstract: A process for the preparation of a solid, orally administrable pharmaceutical composition, comprising 5-chloro-N-({(5)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide comprising preparing granules in hydrophilized form using fluidized bed granulation for moist granulation, adding additives, compressing to form a tablet, and coating the tablet.Type: GrantFiled: March 10, 2014Date of Patent: March 15, 2016Assignee: BAYER INTELLECTUAL PROPERTY GMBHInventor: Klaus Benke
-
Patent number: 9259456Abstract: This invention provides compositions comprising a protein and an omega-3 fatty acid, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: GrantFiled: August 31, 2006Date of Patent: February 16, 2016Assignee: Oramed Pharmaceuticals Inc.Inventor: Miriam Kidron
-
Patent number: 9248195Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.Type: GrantFiled: October 15, 2013Date of Patent: February 2, 2016Assignee: Collegium Pharmaceutical, Inc.Inventors: Roman V. Rariy, Alison B. Fleming, Jane Hirsh, Alexander M. Klibanov
-
Patent number: 9233068Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).Type: GrantFiled: October 4, 2012Date of Patent: January 12, 2016Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Qiang Ye, Luis A. Dellamary, Carl Lebel, Jeffrey P. Harris
-
Patent number: 9198871Abstract: An enteric-coated oral dosage form comprising an acid labile active pharmaceutical ingredient where the composition is substantially free of monomeric phthalic acid esters and synthetic oils is described herein. Also provided are methods for making and using the enteric-coated oral dosage form. The disclosed pharmaceutical compositions comprise an enteric coating which includes at least one plasticizer, at least one film-forming agent and optionally at least one anti-sticking agent.Type: GrantFiled: August 15, 2006Date of Patent: December 1, 2015Assignee: Abbott Products GmbHInventors: George Shlieout, Claus-Juergen Koelln, Frithjof Sczesny, Jens Onken, Andreas Koerner
-
Patent number: 9186332Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.Type: GrantFiled: December 13, 2012Date of Patent: November 17, 2015Assignee: Jagotec AGInventors: Guy Vergnault, Pascal Grenier, Christophe Dragan
-
Patent number: 9173847Abstract: Stable tablets and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved or dispersed in an non-aqueous vehicle with improved bioavailability, thereby eliminating the food effect so that the tablet or composition can be administered to a patient irrespective of being in fed or fasted state.Type: GrantFiled: June 9, 2006Date of Patent: November 3, 2015Assignee: VELOXIS PHARMACEUTICALS A/SInventors: Per Holm, Tomas Norling
-
Patent number: 9138412Abstract: The present invention provides a suitable technique namely wet milling and the process for reducing the particle size of efavirenz and making a tablet or capsule formulation with desired bioavailability equivalent to the reference listed drug without loosing its characteristics.Type: GrantFiled: November 4, 2009Date of Patent: September 22, 2015Assignee: HETERO RESEARCH FOUNDATIONInventors: Bandi Parthasaradhi Reddy, Podili Khadgapathi, Goli Kamalakar Reddy
-
Patent number: 9138413Abstract: The present invention comprises a co-processed carbohydrate system, and formulations produced therefrom, which formulations are directly compressible into solid dosage forms, some of which rapidly and completely dissolve or disintegrate in the oral cavity within 60 seconds. The invention also comprises the solid dosage forms produced by directly compressing the co-processed carbohydrate system, some of which, when placed in the oral cavity, shall dissolve or disintegrate, preferably within about 60 seconds.Type: GrantFiled: September 27, 2013Date of Patent: September 22, 2015Assignee: SPI Pharma, Inc.Inventors: Gary T. Norman, Kalyan S. Nuguru, Arun F. Amin, Sarath Chandar
-
Patent number: 9132094Abstract: The present disclosure relates to compositions and pharmaceutical formulations comprising at least one active pharmaceutical ingredient chosen from nitrocatechol derivatives of formula I as defined herein and salts, esters, hydrates, solvates and derivatives thereof and methods of making said compositions and pharmaceutical formulations.Type: GrantFiled: March 31, 2010Date of Patent: September 15, 2015Assignee: BIAL—Portela & Ca, S.A.Inventors: Teófilo Cardoso de Vasconcelos, Ricardo Jorge dos Santos Lima, Rui Cerdeira de Campos Costa
-
Patent number: 9132132Abstract: The present invention relates to stable pharmaceutical compositions comprising linezolid crystalline Form III with one or more pharmaceutically acceptable excipients, wherein the composition retains linezolid in its original crystalline form.Type: GrantFiled: August 29, 2011Date of Patent: September 15, 2015Assignee: HETERO RESEARCH FOUNDATIONInventors: Bandi Parthasaradhi Reddy, Podili Khadgapathi, Goli Kamalakar Reddy, Lekkala Vamshi Krishna
-
Patent number: 9132087Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agents and auris pressure modulators. In these methods, the auris compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of the immunomodulating and/or auris pressure modulating compositions and formulations onto the auris media and/or auris interna target areas, or via perfusion into the auris media and/or auris interna structures.Type: GrantFiled: April 21, 2009Date of Patent: September 15, 2015Assignees: OTONOMY, INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jay Lichter, Andrew M. Trammel, Fabrice Piu, Luis A. Dellamary, Qiang Ye, Carl Lebel, Michael Christopher Scaife, Jeffrey P. Harris
-
Patent number: 9119786Abstract: The present invention relates to the crystalline mono mesylate monohydrate salt of N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide in a definite particle size range, particle size distribution and a specific surface area range, which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions, as well as to pharmaceutical compositions containing said crystalline N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mono mesylate monohydrate having the afore-mentioned particle size range, particle size distribution and specific surface area range.Type: GrantFiled: November 1, 2013Date of Patent: September 1, 2015Assignee: AICURIS GMBH & CO KGInventors: Wilfried Schwab, Alexander Birkmann, Kerstin Paulus, Kurt Vogtli, Dieter Haag, Stephan Maas, Kristian Ruepp
-
Patent number: 9119775Abstract: A method of treating hypoptyalism in a subject is provided. The method includes administering to the subject a pharmaceutical composition that includes pilocarpine and a bioadhesive polymer. The composition dissolves sublingually in the mouth of the subject and adheres to mucous tissues in the buccopharyngeal cavity. The pilocarpine then dissolves and binds to muscarine receptors present in cells of the subject's salivary glands, endobuccal submucous glands and submaxillary glands, is then absorbed by the cells thereby stimulating the glands to produce saliva.Type: GrantFiled: August 12, 2011Date of Patent: September 1, 2015Inventors: Philippe Perovitch, Marc Maury, Jean Deymes
-
Patent number: 9101661Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: October 16, 2014Date of Patent: August 11, 2015Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9101660Abstract: The present invention provides a solid preparation containing an insulin sensitizer and an active ingredient (except insulin sensitizers), which is useful as a therapeutic drug for diabetes and the like, and which is superior in preparation characteristics such as content uniformity and dissolution property of the insulin sensitizer and the active ingredient (except insulin sensitizers), preparation hardness and the like.Type: GrantFiled: October 6, 2003Date of Patent: August 11, 2015Assignee: Takeda Pharmaceutical CompanyInventors: Masahiko Koike, Hiroyoshi Koyama, Naoru Hamaguchi
-
Patent number: 9095614Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: October 16, 2014Date of Patent: August 4, 2015Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9095615Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: October 16, 2014Date of Patent: August 4, 2015Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9089486Abstract: The present invention belongs to the field of pharmaceutical industry and relates to a process for preparing dosage forms containing ezetimibe, comprising the steps of: a) providing a composition comprising ezetimibe, b) sieving a composition comprising a composition of step (a), c) shear mixing of the composition after step (b), preferably the mixing of the composition is carried out by high shear mixing, d) formulation into a dosage form. The present invention also relates to dosage forms containing ezetimibe and ezetimibe and simvastatin, which have been prepared according to the process according to the invention.Type: GrantFiled: February 5, 2010Date of Patent: July 28, 2015Assignee: LEK PHARMACEUTICALS D.D.Inventors: Janez Kerc, Miha Homar, Polona Jurkovic
-
Patent number: 9084439Abstract: The invention provides a smokeless tobacco product comprising a tobacco extract. In some embodiments, the smokeless tobacco product is translucent. The invention further provides methods for making and using the smokeless tobacco product. In certain embodiments, the smokeless tobacco product comprises isomalt, maltitol syrup, and a translucent tobacco extract prepared by ultrafiltration.Type: GrantFiled: September 22, 2011Date of Patent: July 21, 2015Assignee: R.J. Reynolds Tobacco CompanyInventor: Darrell Holton, Jr.
-
Patent number: 9084816Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.Type: GrantFiled: October 16, 2014Date of Patent: July 21, 2015Assignees: PURDUE PHARMA L.P., PURDUE PHARMACEUTICALS L.P.Inventors: William H. McKenna, Richard O. Mannion, Edward P. O'Donnell, Haiyong H. Huang
-
Patent number: 9066858Abstract: A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described.Type: GrantFiled: October 10, 2008Date of Patent: June 30, 2015Assignee: ALTERGON S.A.Inventors: Lorenzo Bellorini, Luca Nocelli, Giorgio Zoppetti
-
Patent number: 9040084Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: GrantFiled: February 12, 2013Date of Patent: May 26, 2015Assignee: Purdue Pharma L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150140086Abstract: The present invention relates to co-extruded pharmaceutical compositions and dosage forms including an active agent, such as an opioid agonist, and an adverse agent, such as an opioid antagonist. Such compositions and dosage forms arc useful for preventing or discouraging tampering, abuse, misuse or diversion of a dosage form containing an active pharmaceutical agent, such as an opioid. The present invention also relates to methods of treating a patient with such a dosage form, as well as kits containing such a dosage form with instructions for using the dosage form to treat a patient.Type: ApplicationFiled: October 14, 2014Publication date: May 21, 2015Inventors: Robert P. Flath, John K. Masselink
-
Publication number: 20150140085Abstract: Oral pharmaceutical formulations of ibrutinib and/or a pharmaceutically acceptable salt thereof, methods for their administration, process of their production, and use of these formulations for the treatment of diseases treatable by ibrutinib such as cancer, inflammatory diseases, and autoimmune diseases.Type: ApplicationFiled: June 26, 2013Publication date: May 21, 2015Applicant: Principia Biopharma Inc.Inventor: David Michael Goldstein
-
Publication number: 20150140094Abstract: A pharmaceutical composition comprising Compound 1, (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid), and at least one excipient selected from: a filler, a diluent, a disintegrant, a surfactant, a binder, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering an oral pharmaceutical formulation of Compound 1 to the patient.Type: ApplicationFiled: November 14, 2014Publication date: May 21, 2015Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventors: Marinus Jacobus Verwijs, Rossitza Gueorguieva Alargova, Ritu Rohit Kaushik, Irina Nikolaevna Kadiyala, Christopher Young
-
Publication number: 20150140046Abstract: Compounds of general formula (I): R1-Wn-Xm-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-AA9-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, preparation processes, cosmetic or pharmaceutical compositions which contain them and their use in medicine, particularly in the treatment and/or prevention of pain, inflammation, itching, neurological, compulsive and/or neuropsychiatric diseases and/or disorders and in processes of treatment and/or care of the skin, hair and/or mucous membranes mediated by neuronal exocytosis.Type: ApplicationFiled: April 12, 2013Publication date: May 21, 2015Inventors: Antonio Vicente Ferrer Montiel, Gregorio Fernández Ballester, José María García Antón, Cristina Carreño Serraïma, Núria Almiñana Doménech, Raquel Delgado González
-
Patent number: 9034376Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.Type: GrantFiled: August 14, 2014Date of Patent: May 19, 2015Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
-
Publication number: 20150132378Abstract: The present invention relates to a multilayered coated tablet comprising at least three layers, i.e., first, second and third layer wherein the first and third layers contain at least one active pharmaceutical ingredient and the second layer is either a placebo or an immediate-release drug layer. Further, the tablet has a delayed-release coating, wherein the coating may contain one or more pore-forming agents and/or orifices on one or both sides. Furthermore, it may contain an immediate-release layer of the drug over the delayed-release coating layer. The present invention further relates to processes for preparing such a multilayered coated tablet.Type: ApplicationFiled: June 29, 2012Publication date: May 14, 2015Applicant: RANBAXY LABORATORIES LIMITEDInventors: Murali Krishna Bhavarisetti, Kumaravel Vivek, Sreekanth Narravula, Romi Barat Singh
-
Patent number: 9028869Abstract: The present invention is a solid dosage form for oral administration of ibuprofen comprising a modified release formulation of ibuprofen which provides an immediate burst effect and thereafter a sustained release of sufficient ibuprofen to maintain blood levels at least 6.4 ?g/ml over an extended period of at least 8 hours following administering of a single dose.Type: GrantFiled: February 16, 2010Date of Patent: May 12, 2015Assignee: Shasun Pharmaceuticals LimitedInventors: Michael Hite, Cathy Federici, Alan Brunelle, Stephen Turner
-
Publication number: 20150125523Abstract: The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease.Type: ApplicationFiled: December 15, 2014Publication date: May 7, 2015Inventors: SERGIO BARONI, Salvatore Bellinvia, Francesca Viti
-
Patent number: 9023390Abstract: Sustained-release oral pharmaceutical compositions and methods of use, wherein the compositions are in a single dosage form and include an amine-containing compound (including salts thereof), a salt of a non-steroidal anti-inflammatory drug (NSAID), and a hydrophilic matrix.Type: GrantFiled: December 31, 2009Date of Patent: May 5, 2015Assignee: Upsher-Smith Laboratories, Inc.Inventors: Christian F. Wertz, James S. Jensen, Victoria Ann O'Neill, Sean B. Mahoney, Stephen M. Berge
-
Publication number: 20150118302Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.Type: ApplicationFiled: October 29, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Publication number: 20150118295Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.Type: ApplicationFiled: September 12, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Publication number: 20150118303Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.Type: ApplicationFiled: November 12, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Publication number: 20150118300Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.Type: ApplicationFiled: July 17, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Publication number: 20150118301Abstract: Described are oral dosage forms that contain abuse-deterrent features and that contain core-shell polymers that include an active pharmaceutical ingredient, with particular examples including immediate release dosage forms that contain a drug that is commonly susceptible to abuse.Type: ApplicationFiled: September 4, 2014Publication date: April 30, 2015Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
-
Publication number: 20150118296Abstract: The present invention relates to controlled release pharmaceutical compositions comprising budesonide. The invention also relates to processes for the preparation of such compositions and using those compositions in the treatment of Inflammatory Bowel Disease and Irritable Bowel Syndrome including mild to moderate ulcerative colitis.Type: ApplicationFiled: October 22, 2014Publication date: April 30, 2015Inventors: Shushrut Krishnaji Kulkarni, Ajaykumar Handa, Pushpendra Pratap Singh, Ankur Paresh Shah
-
Patent number: 9017722Abstract: A tablet characterized by comprising 5-methyl-1-phenyl-2-(1H)-pyridone as the main ingredient and, based on the main ingredient, 10 to 50 wt. % excipient, 5 to 40 wt. % disintegrator, 1 to 10 wt. % binder, 0.5 to 5 wt. % lubricant, 2 to 6 wt. % coating basis, and 0.05 to 3 wt. % light-shielding agent, wherein the odor or bitterness of the 5-methyl-1-phenyl-2-(1H)-pyridone is masked and the light stability is improved.Type: GrantFiled: October 26, 2012Date of Patent: April 28, 2015Assignee: Intermune, Inc.Inventors: Gakuji Kiyonaka, Yoshihiro Furuya, Yusuke Suzuki
-
Patent number: 9017721Abstract: The present invention relates to methods for producing particles of diclofenac using dry milling processes as well as compositions comprising diclofenac, medicaments produced using diclofenac in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of diclofenac administered by way of said medicaments.Type: GrantFiled: May 14, 2014Date of Patent: April 28, 2015Assignee: iCeutica Pty Ltd.Inventors: Aaron Dodd, Felix Meiser, Marck Norret, Adrian Russell, H William Bosch
-
Publication number: 20150110869Abstract: The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infections, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutical composition comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and, optionally, a moisture barrier coating. A method of manufacturing an adhesive-free pharmaceutical composition is also disclosed.Type: ApplicationFiled: May 28, 2013Publication date: April 23, 2015Inventors: Mathew Philip, Naresh Talwar